Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal latent tuberculosis infection testing and treatment with active TB case finding in Ca Mau Province
ACTRN12622000115730Phase 4Not yet recruiting
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isoniazid and rifapentine in latent tuberculosis infection (LTBI) and Tuberculosis (TB) (2 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoint: Population prevalence of bacteriologically confirmed tuberculosis. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
isoniazidrifapentine
03
Conditions
latent tuberculosis infection (LTBI)Tuberculosis (TB)
Beyond the preview
Go deeper on ACTRN12622000115730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000115730.